Table 2.
Patient characteristics
| Cases with clinical and pathological NS (Cases 1–3) | Case without clinical NS but with pathological NS (Case 4) | Cases without clinical and pathological NS (n = 65) | |
|---|---|---|---|
| Biopsy procedure | |||
| US-guided CNB | 2 | 0 | 27 |
| —median number of samples (range) | 3.5 (2–5) samples | 4 (1–9)b samples | |
| US-guided VAB | 1 | 1 | 31 |
| Stereotactic VAB | 0 | 0 | 7 |
| Neoadjuvant chemotherapy | |||
| Yes | 2 | 0 | 8 |
| —median days from biopsy to surgery (range) | 211 (104–214) days | 212 (147–292)c days | |
| No | 1 | 1 | 57 |
| —median days from biopsy to surgery (range) | 93 days | 71 days | 98 (47–162)d days |
| Histology | |||
| DCIS | 0 | 0 | 10 |
| IDC | 2 | 1 | 47 |
| ILC | 0 | 0 | 6 |
| Invasive micropapillary carcinoma | 1 | 0 | 0 |
| Others | 0 | 0 | 2 |
| Histological grade | |||
| 1 | 0 | 1 | 21 |
| 2 | 0 | 0 | 24 |
| 3 | 3 | 0 | 10 |
| Lymph invasion | |||
| Yes | 3 | 1 | 34 |
| No | 0 | 0 | 31 |
| Vascular invasion | |||
| Yes | 3 | 1 | 8 |
| No | 0 | 0 | 57 |
| Subtypea | |||
| Luminal A | 0 | 1 | 25 |
| Luminal B | 1 | 0 | 13 |
| Luminal-HER2 | 1 | 0 | 7 |
| Pure HER2 | 1 | 0 | 6 |
| Triple negative | 0 | 0 | 4 |
US, ultrasonography; CNB, core needle biopsy; VAB, vacuum-assisted biopsy; NS, neoplastic seeding; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
aInvasive carcinoma. Luminal A: estrogen recepter (ER)-positive (Allred score ≥ 3), human epidermal growth factor type 2 (HER2)-negative, Allred of ER + progesterone receptor (PR) ≥13, histological grade 1 or 2, and Ki67 ≤ 20%. Luminal B: ER-positive and HER2-negative, excepting luminal A. Luminal- HER2: ER-positive and HER2-positive. Pure HER2: ER-negative and HER2-positive. Triple negative: ER-negative and HER2-negative.
bFour unknown cases.
cOne unknown case.
dThree unknown cases.